Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pbserum Plus and Pbserum HA 2.0 in Aesthetic and Regenerative Bioremodeling
NCT07908953Not yet recruiting
- Sponsor
- Antony Barbosa Institute
- Start
- Nov 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial of PBSerum Plus and pbserum HA 2.0 in Skin laxity, localized adiposity (AL), cellulite and 2 more, sponsored by Antony Barbosa Institute. Primary endpoints: Clinical Safety at 180 days, Change in Skin Elasticity Measured by Cutometry at 180 days and 3 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
PBSerum Pluspbserum HA 2.0
03
Conditions
Skin laxitylocalized adiposity (AL)cellulitefibrosispathological scarring (PS)
Beyond the preview
Go deeper on NCT07908953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07908953.